28.05.2013
- AstraZeneca is to buy Omthera Pharmaceuticals for as much as $443 million to build up its cardiovascular drug business, a priority area for Britain's second-biggest drugmaker. The...
23.05.2013
- The tide may have started to turn for initial public offerings from U.S. biotechnology companies, as a rising stock market, low interest rates and a lack of market volatility...
